GlassScriptPhysician profile
Craig Lee Moergen
NPI 1174724918
$2,225.07
in general payments reported to CMS, 2019-2025
14 companies · $20.19 in 2025
The $20.19 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $367 · 2022: $1,522 · 2023: $316 · 2025: $20.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $336.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $532.83 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $463.34 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $222.77 | 2022-2023 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $196.36 | 2021-2022 | |
| Alkermes, INC. | $162.82 | 2021-2023 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $132.83 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.29 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $101.52 | 2022 | |
| Lundbeck LLC | $79.88 | 2022-2023 | Rexulti |
| Indivior INC. | $73.18 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $69.60 | 2021-2023 | Austedo |
| Merck Sharp & Dohme LLC | $49.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.54 | 2022 | |
| Axsome Therapeutics, INC. | $18.51 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Moergen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.